title: Rising population cost for treating people living with HIV in the UK, 1997-2013.
abstract: BACKGROUND
  The number of people living with HIV (PLHIV) is increasing in the UK. This study estimated the annual population cost of providing HIV services in the UK, 1997-2006 and projected them 2007-2013.
  
  
  METHODS
  Annual cost of HIV treatment for PLHIV by stage of HIV infection and type of ART was calculated (UK pounds, 2006 prices). Population costs were derived by multiplying the number of PLHIV by their annual cost for 1997-2006 and projected 2007-2013.
  
  
  RESULTS
  Average annual treatment costs across all stages of HIV infection ranged from £17,034 in 1997 to £18,087 in 2006 for PLHIV on mono-therapy and from £27,649 in 1997 to £32,322 in 2006 for those on quadruple-or-more ART. The number of PLHIV using NHS services rose from 16,075 to 52,083 in 2006 and was projected to increase to 78,370 by 2013. Annual population cost rose from £104 million in 1997 to £483 million in 2006, with a projected annual cost between £721 and £758 million by 2013. When including community care costs, costs increased from £164 million in 1997, to £683 million in 2006 and between £1,019 and £1,065 million in 2013.
  
  
  CONCLUSIONS
  Increased number of PLHIV using NHS services resulted in rising UK population costs. Population costs are expected to continue to increase, partly due to PLHIV's longer survival on ART and the relative lack of success of HIV preventing programs. Where possible, the cost of HIV treatment and care needs to be reduced without reducing the quality of services, and prevention programs need to become more effective. While high income countries are struggling to meet these increasing costs, middle- and lower-income countries with larger epidemics are likely to find it even more difficult to meet these increasing demands, given that they have fewer resources.
authors.affiliation: NPMS-HHC Coordinating and Analytic Centre, London, United Kingdom.
authors.forename: Sundhiya
authors.initials: S
authors.lastname: Mandalia
authors.forename: Roshni
authors.initials: R
authors.lastname: Mandalia
authors.forename: Gary
authors.initials: G
authors.lastname: Lo
authors.forename: Tim
authors.initials: T
authors.lastname: Chadborn
authors.forename: Peter
authors.initials: P
authors.lastname: Sharott
authors.forename: Mike
authors.initials: M
authors.lastname: Youle
authors.forename: Jane
authors.initials: J
authors.lastname: Anderson
authors.forename: Guy
authors.initials: G
authors.lastname: Baily
authors.forename: Ray
authors.initials: R
authors.lastname: Brettle
authors.forename: Martin
authors.initials: M
authors.lastname: Fisher
authors.forename: Mark
authors.initials: M
authors.lastname: Gompels
authors.forename: George
authors.initials: G
authors.lastname: Kinghorn
authors.forename: Margaret
authors.initials: M
authors.lastname: Johnson
authors.forename: Brendan
authors.initials: B
authors.lastname: McCarron
authors.forename: Anton
authors.initials: A
authors.lastname: Pozniak
authors.forename: Alan
authors.initials: A
authors.lastname: Tang
authors.forename: John
authors.initials: J
authors.lastname: Walsh
authors.forename: David
authors.initials: D
authors.lastname: White
authors.forename: Ian
authors.initials: I
authors.lastname: Williams
authors.forename: Brian
authors.initials: B
authors.lastname: Gazzard
authors.forename: Eduard J
authors.initials: EJ
authors.lastname: Beck
mesh_terms: D000465:Algorithms; D019380:Anti-HIV Agents / Q000191:economics; D023241:Antiretroviral Therapy, Highly Active / Q000191:economics; D003365:Costs and Cost Analysis; D004470:Economics, Medical; D005260:Female; D015658:HIV Infections / Q000191:economics* / Q000628:therapy*; D017048:Health Care Costs; D006801:Humans; D008297:Male; D015233:Models, Statistical; D011446:Prospective Studies; D012044:Regression Analysis; D006113:United Kingdom
chemical_list: D019380:Anti-HIV Agents